Background: Cytotherapy has emerged as a transformative modality for complex diseases characterized by immune dysregulation and progressive tissue damage. However, conventional cell-based therapies often address either immune modulation or tissue repair in isolation, limiting long-term clinical efficacy.

Case Presentation: We report a case study employing an integrated cytotherapeutic strategy combining immune effector cell modulation with regenerative stromal support in a patient with refractory disease marked by chronic inflammation, tissue degeneration, and treatment resistance.

Methods: The therapeutic approach involved administration of engineered immune cells designed for targeted immune correction alongside regenerative cell-based constructs aimed at restoring tissue integrity and microenvironmental balance. Clinical, molecular, and functional outcomes were longitudinally assessed.

Results: The combined cytotherapy resulted in sustained disease stabilization, improved functional outcomes, and normalization of inflammatory biomarkers without significant adverse events. Evidence of immune recalibration and tissue regeneration was observed, supporting a synergistic therapeutic effect.

Conclusion: This case demonstrates the feasibility and therapeutic potential of integrated cytotherapy for complex disease management. The findings support further development of combinatorial immune–regenerative cytotherapeutic paradigms and underscore the need for systematic clinical evaluation.